Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 10/20 | 0.41 |
| ▸ | NAMPT | P43490 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13963915 | 0.89 | FAAH (0.48) | CSNK1ESMN1; SMN2 | |
| SCHEMBL13964279 | 0.88 | NAMPT (0.41) | NAMPTSMN1; SMN2USP2ALDH1A1GAA | |
| SCHEMBL4223401 | 0.86 | CSNK1E (0.43) | CSNK1EALDH1A1TSHR | |
| SCHEMBL13963914 | 0.85 | KMT2A (0.47) | CSNK1EGAA | |
| SCHEMBL13964280 | 0.83 | NAMPT (0.49) | CSNK1ENAMPT | |
| SCHEMBL14368381 | 0.82 | CSNK1E (0.47) | CSNK1ESMN1; SMN2ALDH1A1 | |
| SCHEMBL14368487 | 0.82 | CSNK1E (0.47) | CSNK1ESMN1; SMN2GAALMNA | |
| SCHEMBL4213339 | 0.82 | MEN1 (0.53) | CSNK1ESMN1; SMN2ALDH1A1GAATSHR | |
| SCHEMBL13963931 | 0.81 | CSNK1E (0.51) | CSNK1E | |
| SCHEMBL14368471 | 0.80 | NPC1 (0.49) | CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CSNK1E 136/4885NAMPT 2464/4885SMN1; SMN2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.